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Abstract 
BACKGROUND: Urogenital recurrent infections represent a global medical issue in the world, affecting millions of 
women because of dramatic shifts in bacterial composition and concentrations in response to numerous 
endogenous and exogenous factors. Urogenital microbiota forms a mutually beneficial relationship with their host 
and has a major impact on health and disease.  
AIM: This study aimed to compare probiotic therapy versus placebo in Oxidative Stress Values (OSVs) and 
histological features in urogenital infections in female patients.  
METHODS: Forty (n = 40) patients diagnosed with recurrent urogenital infections were recruited to be treated as 
test group (n = 20), receiving Probiotics, and a control group (n = 20), receiving looking similar placebo, both for 
90 days. Both the groups were assessed for total oxidant capacity (d-ROMs test) and biological antioxidant 
potential as iron-reducing activity (BAP test) at baseline, after 1 and 3 months. Histological changes on inner 
vaginal mucosa were also investigated, during the entire study.  
RESULTS: d-ROM assay clearly showed that the values of the test group were significantly different, thus leading 
the general health conditions from a state of high oxidative stress to low oxidative stress levels. Increasing of BAP 
values were more significant, and clinically relevant, in probiotic test group over time.  
CONCLUSION: Our pilot study gave interesting and promising elements to confirm the safety and effectiveness of 
oral probiotics in preventing/reducing the recurrent urogenital infections by an overall modification of inner vaginal 
microbiota. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Urogenital infections are among the most 
common worldwide human infectious diseases [1]. 
Annually it is estimated that one billion women around 
the world suffer from non-sexually transmitted 
urogenital infections, including bacterial vaginosis, 
yeast vaginitis, and urinary tract infection (UTI). 
Although most patients respond to antimicrobial 
treatment, the recurrence rate is high and associated 
with side effects [2], with costs to health care 
providers amounting to over $6 billion annually 
worldwide. [3] UTI can lead to pelvic inflammatory 
disease, infertility, ectopic pregnancy, premature 
labour, low birth weight babies, chronic pain, and 
increased vulnerability to human immunodeficiency 
virus (HIV) and other sexually transmitted infections 
(STIs). The urogenital system is an amalgamation of 
the urinary tract and reproductive system. Because 
both systems are open to the external environment, 
they are susceptible to infections. Some infections are 
introduced from outside, whereas others result from 
imbalances in the microbiota of the urogenital tract.  
Urinary Tract Infections are typically caused 
by bacteria that normally live in the colon and rectum. 
Once bacteria are introduced into the urethra, they 
multiply and travel up to the bladder. E. coli is usually 
the most prevalent organism responsible for UTIs and 
accounts for 80–85% of the total isolates, with 
Staphylococcus saprophyticus being the cause in 5–
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10% [4] [5]. Other bacterial causing UTIs include 
Klebsiella, Proteus, Pseudomonas, Enterococcus, 
Enterobacter spp. Etc. Women are especially more 
prone to developing UTIs due to anatomical factors 
that allow quick bacterial access to the bladder, poor 
hygiene; sexual intercourse and use of contraceptive 
are also contributory factors. Other complications 
caused by UTIs are a bladder infection (cystitis), 
urethra infection (urethritis), kidney infection 
(pyelonephritis) and ureter (ureteritis) [6] [7] The main 
clinical and biological aspects reported in UTIs are 
briefly listed in Table 1.  
Table 1: UTIs Common Features 
________________________________________________________________________ 
 
 A strong, persistent urge to urinate. 
 A burning sensation when urinating. 
 Passing frequent, small amounts of urine. 
 Urine that appears cloudy. 
 Urine that appears red, a sign of blood in the urine. 
 Strong-smelling urine. 
 Pelvic pain. 
________________________________________________________________________ 
 
Recent studies have emphasised the 
importance of a healthy, lactobacilli dominated 
microbiota not only to prevent sexually transmitted 
diseases and preterm labour [8] but also to maintain 
the quality of life of women [9] [10]. The depletion of 
lactobacilli organisms in women susceptible to urinary 
and vaginal infections raised the question of whether 
artificial supplementation of lactobacilli could lower 
infection rates [8] [9] [10]. Nevertheless, drug 
resistance to commonly used antibiotics (e.g., 
trimethoprim/sulfamethoxazole) is increasing among 
uro-pathogens and patients are trying continuous 
alternative natural remedies such as cranberry juice, 
which appears to contain antiadhesive compounds 
that are active against uro-pathogens and can help 
prevent UTIs. Preventive therapies for UTIs are 
currently almost completely dependent on the use of 
antibiotics. In real terms, no true prophylaxis exists: 
current therapy involves long-term, low-dose antibiotic 
treatment, which involves the active killing of bacteria 
that enter the bladder. To develop a non-
chemotherapeutic means to restore and maintain a 
healthy urogenital tract, probiotic therapy using 
lactobacilli has been considered, and there is 
evidence to indicate that certain strains can be 
effective when inserted directly into the vagina or 
when ascending from the rectum after oral ingestion 
[11] [12] [13]. Two strains, Lactobacillus rhamnosus 
and Lactobacillus fermentum, appear to be particularly 
adept at the latter [11] [12] [13] [14]. Repeated intake 
of probiotics could be important not only in women 
subjected to recurrent urogenital infections but also for 
all the healthy women to prevent severe infections 
and superinfections of their vaginal mucosa; in fact, 
the urogenital environment is often altered, and 
lactobacilli are decreased, thereby increasing the risk 
of locally acute infection [13]. Probiotics have been 
demonstrated to be able to protect against UTIs, 
maintaining the vaginal microbiome in proper balance. 
Researches in this field have shown that daily 
administration of Lactobacillus rhamnosus and 
Lactobacillus fermentum, specifically, can positively 
improve vaginal flora. 
The aim of this pilot small-sized study is to 
investigate, in a 90days long clinical trial, whether 
daily administration of probiotics replacing lactobacilli 
(Hyperbiotics PRO-Women) can influence the vaginal 
microbiota.  
 
Material and Methods 
 
The present study was multicentric, entirely 
carried out in Italian clinics and healthcare buildings. 
All patients involved in this study were requested to 
read, understand and sign an informed consent. The 
study was conducted in compliance with the "Ethical 
principles for medical research involving human 
subjects" of Helsinki Declaration. Patients received a 
verbal description of the clinical protocol to be 
followed in this proposal of a clinical study.  
 
Subjects recruited 
A group of 51 patients were randomly 
recruited, after a careful preliminary screening for 
inclusion and exclusion criteria (Figure 1): patients 
receiving antibiotic therapy were excluded from the 
study.  
 
Figure 1: Patient recruitment and selection 
 
Urine samples were analysed in private 
microbiological labs to assess the pathogens 
underlying the infections. A positive result was mainly 
found with specific pathogens, like E Coli (found in 
44/51 patients) and Candida spp (found in 37/51 
patients). Inclusion criteria were recurrent UTIs in 
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patients reporting dysuria, frequency, urgency, and 
abdominal/flank pain with or without fever. Forty (n = 
40) patients diagnosed with recurrent urogenital 
infections were recruited in this study. Half of them 
has been treated as test group (n = 20), receiving 
Probiotics investigated in this study, and a a control 
group (n = 20), receiving tablets looking similar to 
probiotics: tablets were administered for 90 days.  
Table 2: Subject Selection Criteria 
________________________________________________________________________ 
Inclusion Criteria 
a. Caucasian aged between 18-50 years. 
b. Volunteer to participate in the study. 
c. Diagnosed with recurrent urogenital infection. 
Exclusion Criteria 
a. Any systemic disease like liver, kidney and thyroid. 
b. Recent surgical treatments. 
c. Pregnant Women. 
d. Smoking habits. 
e. Patients with sexually transmitted viruses onset on vaginal mucosa. 
f. Patients with frequently recurring complicated vaginitis with a high fever. 
g. Diseases are leading to influence oxidative stress, like syndromic conditions 
& rheumatological diseases. 
h. Subject received antibiotics for the last 3 months and/or during the study 
i. Subjects received immunosuppressive drugs 
________________________________________________________________________ 
 
Both the groups were assessed for total 
oxidant capacity (d-ROMs test) and biological 
antioxidant potential as iron-reducing activity (BAP 
test) at baseline, after 1 and 3 months. Histological 
changes on inner vaginal mucosa were also 
investigated, during the entire study. The investigated 
probiotics were administered as oral tablets, thrice a 
day for the first month, and one tablet per day for the 
remaining two months (a total of 90 days was 
considered enough to get significative results). 
Variations in tablets administration, in patients’ 
compliance and other variations of protocol, were also 
recorded and reported in the final results.  
 
Oxidative Stress Assay 
The technical procedure for the evaluation of 
oxidative stress has been previously reported [15]. 
Oxidative stress assessment was performed using an 
integrated analytical system composed of a 
photometer and a mini-centrifuge (FRAS4, H&D 
S.R.L., Parma, Italy). Samples of whole capillary 
blood were taken by a finger puncture in a heparinized 
tube and immediately centrifuged; a small amount of 
samples plasma (10 μL) was thereafter tested for total 
oxidant capacity (d-ROMs test) and biological 
antioxidant potential as iron-reducing activity (BAP 
test) (Diacron International S.R.L., Grosseto, Italy). 
The d-ROMs test is based on the ability of a plasma 
sample to oxidise the N,N-Diethyl-p-
phenylenediamine to its radical cation; the reaction is 
monitored photometrically at 37°C at 505 nm, and the 
results are expressed as Carratelli Units (CARR U, 
ΔAbs5050 nm/min). The oxidant capacity of plasma 
against N,N-Diethyl-p-phenylenediamine is mainly due 
to hydroperoxides, with the contribution of ferroxidase 
activity of ceruloplasmin and myeloperoxidase. 
Normal Values of d-ROMs Test range between 250 
and 300 CARR Units. The BAP test is based on the 
ability of a plasma sample to reduce the iron of a 
coloured complex containing ferric ions to its ferrous 
derivative, not coloured; the reaction is monitored 
photometrically at 37°C at 505 nm, and the results are 
expressed in mol/L of reduced iron (using ascorbic 
acid as standard reference). Such biological 
antioxidant potential is mainly due to vitamin C, uric 
acid, bilirubin, albumin and tocopherols 
hydroperoxides. Normal values of BAP test are 
assessed over 2200 μM. BAP test values over 2200 
μM was detected on the same machine, by using the 
same lot of kits; all tests were performed by the same 
operator in each of the sampling points, and the 
analytical instrumentation was calibrated before the 
analytical session using plasma with known values of 
d-ROMs and BAP test. To further check the reliability 
of the analysis mean, it was performed the same tests 
on samples of whole capillary blood taken from 5 
healthy volunteers (recruited from the research staff) 
as a control. For each patient, a sample of capillary 
blood was taken up and subjected to BAP-test 
(normal values >2200 μM) and d-ROMs test (normal 
values between 250 and 300 U CARR). After 30 days 
(T1) and after 90 days (T2) the same assay was 
performed for Test-group and Control-group, as well 
as for healthy patients [16].  
 
Microbiological assays 
Patients of both groups were subjected to 
sampling in the inner part of their vaginal mucosa, for 
Gram staining examination. A Gram-staining system, 
proven to be effective in assessing the physiology of 
healthy vaginal flora was performed [15] [16]. Sealed 
packages containing the swabs, slides and transport 
medium for each subject were labelled and distributed 
by physicians to patients of each group. During the 
examination with a speculum, three cotton-tipped 
swabs of upper vaginal secretions were taken up. A 
first swab was rolled against a glass slide, which was 
sprayed immediately with cytological fixative. A 
second swab was placed in a modified Amies clear 
transport medium, and the third swab was rolled onto 
a glass slide which was air-dried. The air-dried slide 
was delivered to the laboratory within 8 hours. All 
slides were heat-fixed and then Gram-stained. The 
Gram-stained slides were prepared by expert 
laboratory technicians. Each of two technicians 
independently assessed the quality (clarity and 
preservation of Gram-negative and positive 
organisms) of each slide. The same examinations 
were carried out at intervals T1 and T2.  
 
Probiotics 
The probiotics used in this study are made 
with 6 targeted probiotic strains (L. plantarum, L. 
fermentum, L. acidophilus, L. reuteri, L. rhanmnosus, 
B. bifidum). Each probiotic tablet contains more than 5 
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billion Colony Forming Units. The probiotics used in 
this study have been created and produced to support 
digestive, urinary, and immune function, by combining 
the efficacy of cranberry extract with the clinically 
studied effects of naturally occurring D-Mannose. D-
Mannose actively works to prevent undesirable 
recurrent pathologies, like bacterial infections, located 
in the urinary tract.  
 
Statistical Analysis 
All data were collected and statistically 
evaluated. T0 data were statistically compared with T1 
and T2 data, using “paired t-test”.  
 
 
Results 
 
All recruited patients were compliant to this 
pilot study: no patients reported adverse reactions, 
and none dropped out of the study before the 
conclusion of the experimental stages. Free radical 
production occurs continuously in the cell during 
metabolism. These radicals (hydroxyl, superoxide 
anion, nitric oxide, etc.) are in part toxic to cell and cell 
membranes; however, they are normally controlled by 
countervailing biologic mechanisms. Severe oxidative 
stress produces ROS and induces uncontrolled lipid 
peroxidation [17]. Urinary tract infection causes 
oxidative stress, increases lipid peroxidation level, and 
leads to insufficiency of antioxidant enzymes [18]. 
Oxidative stress in test and control groups showed 
significant differences among baseline (T0) and at the 
end of the study, i.e. 90 Days (T2). The results 
showed significantly higher levels of oxidative stress 
at baseline in the test group compared to the control 
group (Table 3).  
Table 3: Test group:  oxidative stress values 
 BAP Test (mmol/L) d-ROM Test (U CARR) 
Group T0 T1 T2 T0-T1 % 
Variation 
T0-T2% 
Variation 
T0 T1 T2 T0-T1 % 
Variation 
T0-T2% 
Variation 
Test  1629 2199 2365 34.99% 45.18% 432 358 322 -17.12% -25.46% 
Control 1645 1905 1805 15.80% 9.72% 440 450 457 2.27% 3.86% 
 
The oxidative stress reduction was 
significantly lower in the test group, compared to the 
control group. On recruitment (T0), the mean value of 
d-ROMs in test and control group was 432 and 440 
respectively. The first follow up (T1) result in -17.12 % 
decreases in d-Rom values in the test group as 
compared to an increase of 2.27% increase in the 
control group. The second follow (T2) there was 
further decrease in d-ROM value in the test group, i.e. 
total reduction of 25.46% from baseline value as 
compared to control group where d-ROM values 
further increased and reached to 3.86% enhancement 
from baseline to second follow up. On recruitment 
(T0), the mean value of BAP in test and control group 
was 1629 and 1645 respectively. The first follow up 
(T1) result in 34.99 % increases in BAP values in the 
test group as compared to an increase of 15.80% 
increase in the control group. The second follow (T2) 
there was further increase in BAP value in the test 
group, i.e. total improvement of 45.18% from baseline 
value as compared to control group where BAP 
values further decreased and hence reached to only 
9.72% enhancement from baseline to second follow 
up. The ANOVA test showed high statistical 
significance (p < 0.001) between compared data 
(Figure 2 and 3). This statistically significant difference 
in test and control group in both d-ROM and BAP 
values highlights the importance of oral probiotics in 
improving oxidative stress level in cases of urogenital 
infections.  
 
Figure 2: Comparative chart: bap-assay 
 
Histological examinations also confirmed the 
positive feedback from vaginal mucosa in test-group. 
The mature epithelial cells of the surface are returned 
to be largely flattened and fused, and they show small 
dense pyknotic nuclei (< 4 ). The elimination of 
glycogen by lactobacilli causes an acidic pH that 
protects against bacterial and fungal infections such 
as from candida albicans.  
 
Figure 3: Comparative chart: d-ROM-Assay 
Discussion 
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The vaginal environment has an acidic pH; 
this condition helps prevent the proliferation of harmful 
bacteria and maintains lactobacilli levels (beneficial 
bacteria that protect the environment). Vaginal pH 
balance can be influenced by some factors such as 
menstrual flow, antibiotic intake, excessive hygiene, 
and use of an IUD (intrauterine device), sperm. If the 
pH changes, there may be an excessive development 
of anaerobic organisms that replace the normal 
lactobacilli, causing bacterial vaginosis. Women of 
reproductive age, between 15 and 44 years, are the 
category most exposed to risk. In many cases the 
infection is asymptomatic, but symptoms such as 
light-coloured vaginal secretions, a strong odour, 
especially after sexual intercourse, more rarely pain, 
itching and burning during urination can occur. The 
causes of bacterial vaginosis are not fully known as 
their link to sexual activity has not been fully 
understood. However, an increased incidence of this 
infection was found in women with many partners. 
Bacterial vaginosis can be relapsing, and if it is not 
treated, it can give rise to complications. For example, 
if it arises during pregnancy, it may increase the risk 
of spontaneous abortion or premature birth [19].  
The application of exogenous organisms, 
such as lactobacilli, to the host, is termed probiotics, 
which is broadly defined as a living microorganism 
administered to promote the health of the host by 
treating or preventing disease [20]. The results of this 
study are inconsistent with the previous studies that 
also advocated the beneficial effects of supplementing 
oral probiotics for prevention of urogenital infection 
[12] [20]. Study by Anukam et al. reported in their 
study an effective 90% improvement of bacterial 
vaginosis using probiotic lactobacilli [21]. In vivo study 
concluded by Pascual et al indicated that the probiotic 
produced both preventative and curative effects on E. 
coli growth [22]. Studies affirmed that healthy 
epithelial and mucosal tissues, without any 
oncological onset, equally in younger and older 
patients, are the first step towards the protective 
barrier made by probiotics, that has widely 
demonstrated to prevent colonisation by pathogenic 
microorganisms [23] [24]. There is good clinical 
evidence to show that the intestinal and urogenital 
microbiota have a central role in maintaining both the 
health and wellbeing of humans. Furthermore, the use 
of good bacteria to replace or augment bacterial 
populations is increasingly achieving scientific 
acceptance. 
In conclusion, the role of the human 
microbiota in urogenital women’s health has been 
demonstrated to influence the duration, the relapses 
and the severity of infective episodes. Microbiota has 
also been related to changes in women’s physiology 
during pregnancy and some dysmetabolic diseases. 
The oxidative stress seems to have the role of a 
biological marker, highlighting such conditions of 
inflammatory stress that may lead to superinfections 
or histological changes. Some studies have 
demonstrated the positive effects of many 
nutraceuticals and probiotics in regulating the 
commensal microbiota composition and distribution: 
these effects reflect biology and physiology of tissues 
involved, thus preventing and reducing the severity of 
infections and related inflammatory phenomena. In 
our pilot study, significant improvements have been 
reported in test-Group, related to systemic oxidative 
stress (BAP/d-ROMs), confirming the positive 
influence of probiotics on preventing/reducing UTIs. 
Histological findings describing the gram-staining of 
the vaginal inner mucosa, before and after probiotics 
treatment, in test-group reported a healthy vaginal 
microbiota. Our results, in conclusion, in this 
preliminary study, limited by the small size of involved 
patients, suggest that a daily probiotic administration 
should represent a useful tool for improving the 
women's overall health, with a specific benefit on 
UTIs, with no adverse effects. This approach may 
provide a valuable addition to the current therapeutic 
options for UTIs in women also by regulating the local 
mucosal microbiota.  
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